Glaxosmithkline | GSK - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Amgen USD 5.87B 1.02B 2026-03
AstraZeneca USD 12.86B 251M 2026-06
Aurora Cannabis CAD 29.79M 16.83M 2026-03
Bausch Health Companies USD 2.08B 294M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Canopy Growth CAD 8.26M 13.2M 2026-03
Corcept Therapeutics USD 252.09M 90.07M 2026-06
Drreddys Laboratories INR 43.04B 3.77B 2026-03
Eli Lilly USD 16.22B 301.7M 2026-03
GlaxoSmithKline GBP 6.51B 757M 2026-06
Glaxosmithkline GBP 5.75B 2.99B 2026-03
J&J USD 18.55B 1.31B 2026-06
Merck USD 12.09B 1.24B 2026-03
Novartis USD 11.24B 1.18B 2026-06
Pacira USD 133.91M 7.27M 2026-06
Perrigo USD 313.9M 11.6M 2026-06
Pfizer USD -248M 11.29B 2026-06
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 136.19M 10.11M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Sanofi EUR 8.71B 602M 2026-06
Supernus Pharmaceuticals USD 160.06M 30.7M 2026-06
Takeda JPY 813.22B 124.39B 2026-06
Teva Pharmaceutical Industries USD 2.15B 45M 2026-06
Zoetis USD 1.76B 140M 2026-06